Following challenges with its drug candidate bexotegrast and announcement of a limited-duration stockholder rights program, ...

No Patient Left Behind says that drug value assessments used in countries like Canada and Germany undervalue innovative ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

The FDA has lost several senior employees in recent weeks, including some who have been at the agency for more than two ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...